SpeeDx announced it will expand its U.S.-based operations with the construction of new clinical testing facilities in Austin, TX.
The site will house a range of instrumentation to facilitate clinical trial testing activities in addition to its diagnostic services, the company said.
SpeeDx is an Australian-based private company with subsidiary offices in Austin and London and distributors across Europe. The company specializes in molecular diagnostic tests based on real-time polymerase chain reaction (qPCR) technology.
In June, SpeeDx received breakthrough device designation from the U.S. Food and Drug Administration for its ResistancePlus GC test for detecting Neisseria gonorrhoeae bacteria.
